2026年4月28日，中国抗体-B（股票代码：03681）在港交所发布公告，拟于股东周年大会上授予董事一项股份购回授权，最高规模可达公司于决议案获通过当日已发行股本（不包括库存在内）的10%。本次购回有望以香港法律及上市规则允许的资金为来源，董事会认为此举符合公司及股东的最佳利益，可望进一步提升回报并优化资本结构。
根据公告，若相关议案在定于2026年6月12日举行的股东周年大会上获审议通过，董事会将在有效期内在香港联交所回购最多约10%的股份。过去十二个月，公司股价最高曾达每股3.76港元，最低为1.10港元。公司董事会强调将根据市况及营运资金状况审慎行使授权，并保证回购计划实施后不会影响公司正常运营。股东名册暂定自6月9日至6月12日暂停办理过户登记。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.